0.9755
Precedente Chiudi:
$1.03
Aprire:
$1
Volume 24 ore:
63,631
Relative Volume:
0.25
Capitalizzazione di mercato:
$4.24M
Reddito:
$79,300
Utile/perdita netta:
$-6.92M
Rapporto P/E:
-0.0514
EPS:
-18.9818
Flusso di cassa netto:
$-5.34M
1 W Prestazione:
-15.91%
1M Prestazione:
-33.64%
6M Prestazione:
-49.72%
1 anno Prestazione:
+18.82%
Virax Biolabs Group Ltd Stock (VRAX) Company Profile
Nome
Virax Biolabs Group Ltd
Settore
Industria
Telefono
-
Indirizzo
-
Confronta VRAX con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
VRAX
Virax Biolabs Group Ltd
|
0.9755 | 4.24M | 79,300 | -6.92M | -5.34M | -18.98 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Virax Biolabs Group Ltd Stock (VRAX) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-03-31 | Iniziato | H.C. Wainwright | Buy |
Virax Biolabs Group Ltd Borsa (VRAX) Ultime notizie
FY2025 Earnings Estimate for VRAX Issued By HC Wainwright - Defense World
Virax Biolabs Group (NASDAQ:VRAX) Coverage Initiated by Analysts at HC Wainwright - Defense World
Virax Biolabs' Investigational Diagnostic Tests Has An Attractive Market Opportunity', Analyst Initiates With Buy Rating - Benzinga
Virax Biolabs Group Ltd.’s Innovative Diagnostics and Strategic Collaborations Justify Buy Rating - TipRanks
Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Update - Defense World
Virax Biolabs Group (NASDAQ:VRAX) Stock Price Down 3.9% – What’s Next? - Defense World
Virax Biolabs Launches Clinical Study on T Cell Dysfunction - TipRanks
Virax Biolabs begins UK clinical study on T cell dysfunction - Investing.com India
Breakthrough T Cell Study: Virax Targets Long COVID and Chronic Fatigue Diagnosis Revolution - StockTitan
Virax Biolabs Highlights T-Cell Dysfunction in Post-Infection Syndromes - TipRanks
Virax Biolabs shares T-Cell dysfunction findings - Investing.com India
Virax Biolabs shares T-Cell dysfunction findings By Investing.com - Investing.com South Africa
Game-Changing Long COVID Diagnostic: Virax's New T-Cell Test Shows Promising Results - StockTitan
Virax Biolabs to Present at World Immune Regulation Meeting - TipRanks
Can Virax's T-Cell Research at WIRM 2025 Advance Post-Infection Syndrome Treatment? - StockTitan
Cosmos Health expands distribution of Avian Influenza kits - MSN
Short Interest in Virax Biolabs Group Limited (NASDAQ:VRAX) Expands By 205.8% - Defense World
Virax Biolabs aligns with US vaccine transparency efforts By Investing.com - Investing.com South Africa
Virax Biolabs Aligns with US Health Department on Vaccine Transparency - TipRanks
How Virax's Vaccine Testing Tech Could Capitalize on New Government Transparency Push - StockTitan
EXCLUSIVE: Virax Biolabs Says Its Tech Fits RFK Jr.'s HHS Goals On Vaccine Transparency - Benzinga
Contrasting Virax Biolabs Group (NASDAQ:VRAX) & Oruka Therapeutics (NASDAQ:ORKA) - Defense World
Market Watch: Virax Biolabs Group Ltd (VRAX)’s Noteworthy Drop, Closing at 1.71 - The Dwinnex
Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Down 33.9% in January - Armenian Reporter
Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait - Yahoo Finance
Cosmos Health secures exclusive distribution agreement with Virax Biolabs - Yahoo Finance
Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries - Lelezard
Virax Biolabs Group Ltd (VRAX) Forecast: Revisiting The Past To Gain Insights For The Future - Stocks Register
Virax Biolabs stock soars 45% on Mpox detection kit deal: What you need to know - MSN
Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Down 38.5% in December - Defense World
Virax Biolabs Achieves Shareholder Approvals at Adjourned Annual Meeting - TipRanks
Stock Region Signal Report - substack.com
Why Sangamo Therapeutics Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket - Benzinga
Virax Biolabs Announces Strategic Goals and Developments for 2025 - TipRanks
Virax Biolabs Advances T-Cell Platform with $7.3M War Chest, Expands European Distribution Network - StockTitan
Virax Biolabs Announces Agreement with Tebubio to Expand Distribution of ImmuneSelect across the European Union, Norway, and Switzerland - Marketscreener.com
Virax Biolabs Expands ImmuneSelect Reach in Europe - TipRanks
Virax Biolabs Announces Agreement with Tebubio to Expand Distribution of ImmuneSelect Across the European Union, Norway, and Switzerland - Yahoo Finance
Virax Biolabs Group First Half 2025 Earnings: US$0.89 loss per share (vs US$1.64 loss in 1H 2024) - Simply Wall St
Virax Biolabs Sees Asset Growth Amid Financial Loss - TipRanks
ARMISTICE CAPITAL, LLC Acquires New Stake in Virax Biolabs Group Ltd - GuruFocus.com
Virax Biolabs announces 2024 annual meeting - Investing.com India
Virax Biolabs announces 2024 annual meeting By Investing.com - Investing.com UK
Virax Biolabs Sets Date for 2024 AGM - TipRanks
Virax Biolabs announces distribution agreement with Europa Biosite - TipRanks
Virax Biolabs Group Ltd Azioni (VRAX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):